Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

bayer (schweiz) ag - vericiguatum - compresse rivestite con film - filmtablette: vericiguatum 2.50 mg, cellulosum microcristallinum, carmellosum natricum conexum, hypromellosum, lactosum monohydricum 61.20 mg, magnesii stearas, natrii laurilsulfas, Überzug: hypromellosum, talcum, e 171, pro compresso obducto corresp. natrium 0.80 mg. - herzinsuffizienz - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

bayer (schweiz) ag - vericiguatum - compresse rivestite con film - filmtablette: vericiguatum 5.00 mg, cellulosum microcristallinum, carmellosum natricum conexum, hypromellosum, lactosum monohydricum 58.52 mg, magnesii stearas, natrii laurilsulfas, Überzug: e 172 (rubrum), hypromellosum, talcum, e 171, pro compresso obducto corresp. natrium 0.81 mg. - herzinsuffizienz - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

bayer (schweiz) ag - vericiguatum - compresse rivestite con film - filmtablette: vericiguatum 10.00 mg, cellulosum microcristallinum, carmellosum natricum conexum, hypromellosum, lactosum monohydricum 117.00 mg, magnesii stearas, natrii laurilsulfas, Überzug: e 172 (flavum), hypromellosum, talcum, e 171, pro compresso obducto corresp. natrium 1.65 mg. - herzinsuffizienz - synthetika

Unione Europea - italiano - EMA (European Medicines Agency)

bayer ag - vericiguat - insufficienza cardiaca - terapia cardiaca - treatment of symptomatic chronic heart failure.

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

bayer (schweiz) ag - riociguatum - compresse rivestite con film - riociguatum 0.5 mg, cellulosum microcristallinum, crospovidonum, hypromellosum, lactosum monohydricum 39.8 mg, magnesii stearas, natrii laurilsulfas corresp. natrium 0.00797 mg, Überzug: hydroxypropylcellulosum, hypromellosum, propylenglycolum, e 171, pro compresso obducto. - chronisch-thromboembolische polmonare hypertonie (cteph) und polmonare arterielle hypertonie (pah) - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

bayer (schweiz) ag - riociguatum - compresse rivestite con film - riociguatum 1 mg, cellulosum microcristallinum, crospovidonum, hypromellosum, lactosum monohydricum 39.2 mg, magnesii stearas, natrii laurilsulfas corresp. natrium 0.01594 mg, Überzug: hydroxypropylcellulosum, hypromellosum, propylenglycolum, e 171, e 172 (flavum), pro compresso obducto. - chronisch-thromboembolische polmonare hypertonie (cteph) und polmonare arterielle hypertonie (pah) - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

bayer (schweiz) ag - riociguatum - compresse rivestite con film - riociguatum 1.5 mg, cellulosum microcristallinum, crospovidonum, hypromellosum, lactosum monohydricum 38.7 mg, magnesii stearas, natrii laurilsulfas corresp. natrium 0.01594 mg, Überzug: hydroxypropylcellulosum, hypromellosum, propylenglycolum, e 171, e 172 (flavum), pro compresso obducto. - chronisch-thromboembolische polmonare hypertonie (cteph) und polmonare arterielle hypertonie (pah) - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

bayer (schweiz) ag - riociguatum - compresse rivestite con film - riociguatum 2 mg, cellulosum microcristallinum, crospovidonum, hypromellosum, lactosum monohydricum 38.20 mg, magnesii stearas, natrii laurilsulfas corresp. natrium 0.01594 mg, Überzug: hydroxypropylcellulosum, hypromellosum, propylenglycolum, e 171, e 172 (flavum), e 172 (rubrum), pro compresso obducto. - chronisch-thromboembolische polmonare hypertonie (cteph) und polmonare arterielle hypertonie (pah) - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

bayer (schweiz) ag - riociguatum - compresse rivestite con film - riociguatum 2.5 mg, cellulosum microcristallinum, crospovidonum, hypromellosum, lactosum monohydricum 37.70 mg, magnesii stearas, natrii laurilsulfas corresp. natrium 0.01594 mg, Überzug: hydroxypropylcellulosum, hypromellosum, propylenglycolum, e 171, e 172 (flavum), e 172 (rubrum), pro compresso obducto. - chronisch-thromboembolische polmonare hypertonie (cteph) und polmonare arterielle hypertonie (pah) - synthetika

Unione Europea - italiano - EMA (European Medicines Agency)

bayer ag - riociguat - ipertensione, polmonare - antipertensivi per l'ipertensione arteriosa polmonare - chronic thromboembolic pulmonary hypertension (cteph)adempas is indicated for the treatment of adult patients with who functional class (fc) ii to iii withinoperable cteph,persistent or recurrent cteph after surgical treatment,to improve exercise capacity. pulmonary arterial hypertension (pah)adultsadempas, as monotherapy or in combination with endothelin receptor antagonists, is indicated for the treatment of adult patients with pulmonary arterial hypertension (pah) with who functional class (fc) ii to iii to improve exercise capacity. l'efficacia è stata dimostrata in un pah della popolazione eziologie di idiopatica o ereditaria ipa o pah associata a malattia del tessuto connettivo. paediatricsadempas is indicated for the treatment of pah in paediatric patients aged less than 18 years of age and body weight ≥ 50 kg with who functional class (fc) ii to iii in combination with endothelin receptor antagonists.